Gina Oda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gina Oda has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Cynthia Lucero-Obusan
Office of Public Health, US Department of Veterans Affairs, Veterans Health Administration
19 shared publications - Mark Holodniy
Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA 90024, USA
14 shared publications - Patricia Schirmer
US Department of Veterans Affairs, Public Health National Program Office , Washington, DC, and Palo Alto, California
12 shared publications Mark Holodniy
Gina Oda, Aditya Sharma, Cynthia Lucero-Obusan, Patricia Schirmer, and Mark Holodniy are with the Public Health National Program Office, US Department of Veterans Affairs, Palo Alto, CA, and Washington, DC. Mark Holodniy is also with the Department of Infectious Diseases and Geographic Medicine at Stanford University, Stanford, CA
7 shared publicationsAditya Sharma
Gina Oda, Aditya Sharma, Cynthia Lucero-Obusan, Patricia Schirmer, and Mark Holodniy are with the Public Health National Program Office, US Department of Veterans Affairs, Palo Alto, CA, and Washington, DC. Mark Holodniy is also with the Department of Infectious Diseases and Geographic Medicine at Stanford University, Stanford, CA
4 shared publicationsPatricia Schirmer
Gina Oda, Aditya Sharma, Cynthia Lucero-Obusan, Patricia Schirmer, and Mark Holodniy are with the Public Health National Program Office, US Department of Veterans Affairs, Palo Alto, CA, and Washington, DC. Mark Holodniy is also with the Department of Infectious Diseases and Geographic Medicine at Stanford University, Stanford, CA
4 shared publications
Latest Publications
- 13 August 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (9) , ofaf488
Bacteremic vs Nonbacteremic Shigella Infections in the United States Veterans Health Administration, 2000–2024
Background: Risk factors for Shigella bacteremia are poorly understood. Growing trends in antimicrobial resistance may make treatment of Shigella bacteremia more difficult. We identified risk factors for Shigella bacteremia among Shigella cases who received care in the US Veterans Health Administration (VHA). Methods: We identified adults cared for in VHA with Shigella infection from 2000 to 2024. Shigella bacteremic versus nonbacteremic infections were compared based on patient demographics, comorbidities, outcomes, Shigella species, and antimicrobial resistance. We performed log-binomial regression analysis to estimate association of risk factors with Shigella bacteremia. Results: Of a total of 1962 Shigella infections in 1861 unique patients, 34 (1.7%) had confirmed bacteremia when blood cultures were checked. Shigella species among bacteremia cases included 13 (38.2%) Shigella flexneri and 14 (41.2%) Shigella sonnei, and 7 (2.6%) Shigella nonspeciated. A total of 1266/1962 (64.5%) isolates were tested for antimicrobial susceptibility. No Shigella bacteremia isolates were multidrug resistant; however, isolates from 3 nonbacteremic cases were. All with Shigella bacteremia were hospitalized and 1/34 (2.9%) died within 30 days of infection. Comparing characteristics of patients with Shigella bacteremic versus nonbacteremic infections and adjusting for potential confounders, age ≥65 years and HIV were independent risk factors for Shigella bacteremia (adjusted risk ratio [95% confidence interval] 2.90 [1.46–5.76] and 2.37 [1.11–5.06], respectively). Conclusions: Clinicians should be aware that patients who are elderly and/or have HIV are at higher risk for Shigella bacteremia and that these infections can be severe, requiring hospitalization. At this time, multidrug resistant Shigella strains have not been detected among bacteremic patients in VHA.
- 13 August 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (9) , ofaf488
Bacteremic vs Nonbacteremic Shigella Infections in the United States Veterans Health Administration, 2000–2024
Background: Risk factors for Shigella bacteremia are poorly understood. Growing trends in antimicrobial resistance may make treatment of Shigella bacteremia more difficult. We identified risk factors for Shigella bacteremia among Shigella cases who received care in the US Veterans Health Administration (VHA). Methods: We identified adults cared for in VHA with Shigella infection from 2000 to 2024. Shigella bacteremic versus nonbacteremic infections were compared based on patient demographics, comorbidities, outcomes, Shigella species, and antimicrobial resistance. We performed log-binomial regression analysis to estimate association of risk factors with Shigella bacteremia. Results: Of a total of 1962 Shigella infections in 1861 unique patients, 34 (1.7%) had confirmed bacteremia when blood cultures were checked. Shigella species among bacteremia cases included 13 (38.2%) Shigella flexneri and 14 (41.2%) Shigella sonnei, and 7 (2.6%) Shigella nonspeciated. A total of 1266/1962 (64.5%) isolates were tested for antimicrobial susceptibility. No Shigella bacteremia isolates were multidrug resistant; however, isolates from 3 nonbacteremic cases were. All with Shigella bacteremia were hospitalized and 1/34 (2.9%) died within 30 days of infection. Comparing characteristics of patients with Shigella bacteremic versus nonbacteremic infections and adjusting for potential confounders, age ≥65 years and HIV were independent risk factors for Shigella bacteremia (adjusted risk ratio [95% confidence interval] 2.90 [1.46–5.76] and 2.37 [1.11–5.06], respectively). Conclusions: Clinicians should be aware that patients who are elderly and/or have HIV are at higher risk for Shigella bacteremia and that these infections can be severe, requiring hospitalization. At this time, multidrug resistant Shigella strains have not been detected among bacteremic patients in VHA.
- Open Access
- 27 November 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (12) , ofae698
Risk Factors for Extrapulmonary Tuberculosis Among US Veterans, 1990–2022
Purpose: To determine factors that put US veterans with active tuberculosis at risk for extrapulmonary tuberculosis (EPTB) compared with pulmonary tuberculosis. Methods: We included veterans with laboratory-confirmed tuberculosis from 1990–2022 in our retrospective cohort study. Multivariable logistic regression was used to estimate the association of demographic and clinical risk factors with EPTB. Results: Of 7493 veterans aged 20–100 years (median, 58 years) with laboratory-confirmed tuberculosis, 1397 (19%) had EPTB. The most common EPTB infection among veterans was pleural (31.4%), while meningitis carried the highest mortality risk at 90 days. Factors independently associated with EPTB among veterans were non-Hispanic black race/ethnicity, diabetes mellitus, human immunodeficiency virus infection, severe kidney disease, and all-cause mortality within 90 days after tuberculosis diagnosis. Conclusions: Our study demonstrated several risk factors for EPTB among US veterans. Healthcare providers should be educated regarding patient populations at risk for EPTB, especially given the challenges in diagnosing this disease and the importance of instituting early treatment to prevent severe illness and death.
- 27 November 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (12) , ofae698
Open AccessRisk Factors for Extrapulmonary Tuberculosis Among US Veterans, 1990–2022
Purpose: To determine factors that put US veterans with active tuberculosis at risk for extrapulmonary tuberculosis (EPTB) compared with pulmonary tuberculosis. Methods: We included veterans with laboratory-confirmed tuberculosis from 1990–2022 in our retrospective cohort study. Multivariable logistic regression was used to estimate the association of demographic and clinical risk factors with EPTB. Results: Of 7493 veterans aged 20–100 years (median, 58 years) with laboratory-confirmed tuberculosis, 1397 (19%) had EPTB. The most common EPTB infection among veterans was pleural (31.4%), while meningitis carried the highest mortality risk at 90 days. Factors independently associated with EPTB among veterans were non-Hispanic black race/ethnicity, diabetes mellitus, human immunodeficiency virus infection, severe kidney disease, and all-cause mortality within 90 days after tuberculosis diagnosis. Conclusions: Our study demonstrated several risk factors for EPTB among US veterans. Healthcare providers should be educated regarding patient populations at risk for EPTB, especially given the challenges in diagnosing this disease and the importance of instituting early treatment to prevent severe illness and death.
- Open Access
- 29 June 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (7) , 1327
Clinically Defined Lymphogranuloma Venereum among US Veterans with Human Immunodeficiency Virus, 2016–2023
We applied lymphogranuloma venereum (LGV) clinical case criteria to a cohort of 1381 Veterans positive for HIV and Chlamydia trachomatis (CT) from 2016 from 2023 and analyzed variables to ascertain risk factors for LGV and factors associated with the use of standard treatment regimens. In total, 284/1381 (20.6%) met the criteria for LGV. A total of 179/284 (63%) were probable cases, and 105/284 (37%) were possible cases (those meeting clinical criteria but with concurrent sexually transmitted infections (STI) associated with LGV-like symptoms). None had confirmatory CT L1–L3 testing. A total of 230 LGV cases (81%) presented with proctitis, 71 (25%) with ulcers, and 57 (20.1%) with lymphadenopathy. In total, 66 (23.2%) patients had >1 symptom of LGV. A total of 43 (15%) LGV cases were hospitalized. Primary risk factors for LGV were male birth sex (p = 0.004), men who have sex with men (p < 0.001), and the presence of STIs other than gonorrhea or syphilis (p = 0.011). In total, 124/284 (43.7%) LGV cases received standard recommended treatment regimens. Probable cases were more likely to receive standard treatment than possible cases (p = 0.003). We report that 20.6% of CT cases met clinical criteria for LGV among HIV-infected Veterans and that less than half of cases received recommended treatment regimens, indicating that LGV is likely underestimated and inadequately treated among this US population.
- 29 June 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (7) , 1327
Open AccessClinically Defined Lymphogranuloma Venereum among US Veterans with Human Immunodeficiency Virus, 2016–2023
We applied lymphogranuloma venereum (LGV) clinical case criteria to a cohort of 1381 Veterans positive for HIV and Chlamydia trachomatis (CT) from 2016 from 2023 and analyzed variables to ascertain risk factors for LGV and factors associated with the use of standard treatment regimens. In total, 284/1381 (20.6%) met the criteria for LGV. A total of 179/284 (63%) were probable cases, and 105/284 (37%) were possible cases (those meeting clinical criteria but with concurrent sexually transmitted infections (STI) associated with LGV-like symptoms). None had confirmatory CT L1–L3 testing. A total of 230 LGV cases (81%) presented with proctitis, 71 (25%) with ulcers, and 57 (20.1%) with lymphadenopathy. In total, 66 (23.2%) patients had >1 symptom of LGV. A total of 43 (15%) LGV cases were hospitalized. Primary risk factors for LGV were male birth sex (p = 0.004), men who have sex with men (p < 0.001), and the presence of STIs other than gonorrhea or syphilis (p = 0.011). In total, 124/284 (43.7%) LGV cases received standard recommended treatment regimens. Probable cases were more likely to receive standard treatment than possible cases (p = 0.003). We report that 20.6% of CT cases met clinical criteria for LGV among HIV-infected Veterans and that less than half of cases received recommended treatment regimens, indicating that LGV is likely underestimated and inadequately treated among this US population.
- Open Access
- 22 December 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 229 (Supplement) , S172-S180
Epidemiology of the 2022 Mpox Outbreak in the US Veterans Health Administration
Background: In May 2022, mpox cases were reported in nonendemic countries, including the United States. We examined mpox infections in the Veterans Health Administration (VHA). Methods: Mpox diagnostic and whole genome sequencing (WGS) results, demographics, risk factors, hospitalizations, exposures, deaths, and pharmacy and immunization data were obtained from VHA data sources (23 May 2022–31 May 2023). Results: Of 1144 Veterans tested, 251 (21.9%) were presumptive positive for nonvariola orthopoxvirus (NVO) or confirmed positive for NVO and Monkeypox virus (MPXV). Incidence rate was 7.5 per 100 000 Veterans in care, with the highest rate observed in Veterans aged 25–34 years (13.83 cases per 100 000). Higher odds of NVO or NVO/MPXV positivity was associated with male sex; non-Hispanic Black race/ethnicity; syphilis or human immunodeficiency virus (HIV) positivity; or genital/rectal sample site, whereas older age and vaccination with JYNNEOS or vaccinia (smallpox) had lower odds. Among 209 with confirmatory testing, 90.4% reported intimate contact and/or an epidemiological link, 84.5% were men who have sex with men (MSM), 24.2% received tecovirimat, and 8.1% were hospitalized with 1 death. Eighty-six sequenced samples had evaluable WGS results. All were clade IIb, representing 10 different lineages from 20 states and the District of Columbia. Conclusions: Mpox affected younger, MSM, non-Hispanic Black, and HIV/syphilis-positive men among US Veterans. Viral diversity was noted across geographic regions. At-risk Veterans would benefit from vaccination and risk reduction strategies for mpox and other sexually transmitted infections.
- 22 December 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 229 (Supplement) , S172-S180
Open AccessEpidemiology of the 2022 Mpox Outbreak in the US Veterans Health Administration
Background: In May 2022, mpox cases were reported in nonendemic countries, including the United States. We examined mpox infections in the Veterans Health Administration (VHA). Methods: Mpox diagnostic and whole genome sequencing (WGS) results, demographics, risk factors, hospitalizations, exposures, deaths, and pharmacy and immunization data were obtained from VHA data sources (23 May 2022–31 May 2023). Results: Of 1144 Veterans tested, 251 (21.9%) were presumptive positive for nonvariola orthopoxvirus (NVO) or confirmed positive for NVO and Monkeypox virus (MPXV). Incidence rate was 7.5 per 100 000 Veterans in care, with the highest rate observed in Veterans aged 25–34 years (13.83 cases per 100 000). Higher odds of NVO or NVO/MPXV positivity was associated with male sex; non-Hispanic Black race/ethnicity; syphilis or human immunodeficiency virus (HIV) positivity; or genital/rectal sample site, whereas older age and vaccination with JYNNEOS or vaccinia (smallpox) had lower odds. Among 209 with confirmatory testing, 90.4% reported intimate contact and/or an epidemiological link, 84.5% were men who have sex with men (MSM), 24.2% received tecovirimat, and 8.1% were hospitalized with 1 death. Eighty-six sequenced samples had evaluable WGS results. All were clade IIb, representing 10 different lineages from 20 states and the District of Columbia. Conclusions: Mpox affected younger, MSM, non-Hispanic Black, and HIV/syphilis-positive men among US Veterans. Viral diversity was noted across geographic regions. At-risk Veterans would benefit from vaccination and risk reduction strategies for mpox and other sexually transmitted infections.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1992. Two Decades of Lyme Disease in the U.S. Veterans Health Administration Detected Via Automated Surveillance Methodology, October 1999 - September 2022
Lyme disease is the most common vector-borne disease in the U.S. Incidence of Lyme disease is rising, partly due to climate change, and is likely underreported. We evaluated an automated method to analyze Lyme disease trends over two decades in the Veterans Health Administration (VHA). Methodology *Nelson, C.A., et al. Emerging Infectious Diseases. Vol. 21, No. 9, September 2015 Incidence and Prevalence of Lyme Disease in VHA, Fiscal Years 2000 - 2022 VHA Lyme Disease Average Incidence rates by Demographic Variable, FY 2000 - 2022 Positive Predictive Value of Automated Case-Finding, N=75 *CSTE case definition = the current surveillance definition used by the Centers for Disease Control and Prevention Lyme Disease (Borrelia burgdorferi) 2022 Case Definition | CDC, based on 2021 Council of State and Territorial Epidemiologists Position Statement 21-ID-05: “Modification of Lyme Disease Case Definition”. Automated surveillance methodology for Lyme disease provided an efficient and reasonably accurate estimation of the epidemiology of Lyme disease in VHA. The VHA pattern of Lyme disease geographic expansion in recent years is consistent with CDC national reporting. Providers should be aware of Lyme disease as an emerging threat. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1992. Two Decades of Lyme Disease in the U.S. Veterans Health Administration Detected Via Automated Surveillance Methodology, October 1999 - September 2022
Lyme disease is the most common vector-borne disease in the U.S. Incidence of Lyme disease is rising, partly due to climate change, and is likely underreported. We evaluated an automated method to analyze Lyme disease trends over two decades in the Veterans Health Administration (VHA). Methodology *Nelson, C.A., et al. Emerging Infectious Diseases. Vol. 21, No. 9, September 2015 Incidence and Prevalence of Lyme Disease in VHA, Fiscal Years 2000 - 2022 VHA Lyme Disease Average Incidence rates by Demographic Variable, FY 2000 - 2022 Positive Predictive Value of Automated Case-Finding, N=75 *CSTE case definition = the current surveillance definition used by the Centers for Disease Control and Prevention Lyme Disease (Borrelia burgdorferi) 2022 Case Definition | CDC, based on 2021 Council of State and Territorial Epidemiologists Position Statement 21-ID-05: “Modification of Lyme Disease Case Definition”. Automated surveillance methodology for Lyme disease provided an efficient and reasonably accurate estimation of the epidemiology of Lyme disease in VHA. The VHA pattern of Lyme disease geographic expansion in recent years is consistent with CDC national reporting. Providers should be aware of Lyme disease as an emerging threat. All Authors: No reported disclosures
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
898. Influenza Surveillance in the US Veterans Health Administration (VHA): 2022-2023 Season
Influenza causes seasonal epidemics with substantial morbidity and mortality. Veterans Health Administration’s (VHA) large elderly population is at higher risk for influenza complications, including hospitalization, and death. Herein we summarize VHA’s national annual surveillance data for influenza activity and vaccinations. Influenza-like-illness (ILI) as well as influenza-coded outpatient visits and hospitalizations, laboratory testing, and antivirals were obtained from VHA data sources (10/2/2022-4/22/23) and compared to prior years and CDC data. Vaccinations were captured starting 8/1/2022, with rates calculated based on VHA users in each fiscal year. Influenza RT-PCR positive respiratory samples underwent whole genome sequencing (WGS) to analyze clade and antiviral resistance. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access898. Influenza Surveillance in the US Veterans Health Administration (VHA): 2022-2023 Season
Influenza causes seasonal epidemics with substantial morbidity and mortality. Veterans Health Administration’s (VHA) large elderly population is at higher risk for influenza complications, including hospitalization, and death. Herein we summarize VHA’s national annual surveillance data for influenza activity and vaccinations. Influenza-like-illness (ILI) as well as influenza-coded outpatient visits and hospitalizations, laboratory testing, and antivirals were obtained from VHA data sources (10/2/2022-4/22/23) and compared to prior years and CDC data. Vaccinations were captured starting 8/1/2022, with rates calculated based on VHA users in each fiscal year. Influenza RT-PCR positive respiratory samples underwent whole genome sequencing (WGS) to analyze clade and antiviral resistance. All Authors: No reported disclosures
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1797. Pneumococcal Vaccination in Veterans 65 years and older with Pneumococcus in the Veterans Health Administration (VHA) since November 2021
Pneumococcal infection is a vaccine-preventable illness caused by Streptococcus pneumoniae. In October 2021, the Advisory Committee on Immunization Practices updated pneumococcal vaccine guidelines in all adults >65 years and for adults 19-64 years with certain medical conditions or risk factors. Pneumococcal vaccination among patients >65 years is a national VHA performance measure. We reviewed vaccine status in patients >65 years with pneumococcal infection since guidelines changed. Demographics, pneumococcal vaccination in relation to time of infection and laboratory testing (culture, molecular and urinary antigen) during 11/1/2021-4/11/2023 were retrieved from VHA data sources. Patients aged >65 years with pneumococcus were evaluated and compared to VHA’s electronic quality measurement (eQM) for national pneumococcal vaccination rates. In VHA patients >65 years with pneumococcal infection, nearly 90% had had at least 1 pneumococcal vaccine which was mainly PPSV23 and given on average almost 5 years before infection. VHA could target non-Hispanic Black patients with pneumococcal vaccination efforts and ensure providers are utilizing PCV20 or PCV15+PPSV23 vaccines. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1797. Pneumococcal Vaccination in Veterans 65 years and older with Pneumococcus in the Veterans Health Administration (VHA) since November 2021
Pneumococcal infection is a vaccine-preventable illness caused by Streptococcus pneumoniae. In October 2021, the Advisory Committee on Immunization Practices updated pneumococcal vaccine guidelines in all adults >65 years and for adults 19-64 years with certain medical conditions or risk factors. Pneumococcal vaccination among patients >65 years is a national VHA performance measure. We reviewed vaccine status in patients >65 years with pneumococcal infection since guidelines changed. Demographics, pneumococcal vaccination in relation to time of infection and laboratory testing (culture, molecular and urinary antigen) during 11/1/2021-4/11/2023 were retrieved from VHA data sources. Patients aged >65 years with pneumococcus were evaluated and compared to VHA’s electronic quality measurement (eQM) for national pneumococcal vaccination rates. In VHA patients >65 years with pneumococcal infection, nearly 90% had had at least 1 pneumococcal vaccine which was mainly PPSV23 and given on average almost 5 years before infection. VHA could target non-Hispanic Black patients with pneumococcal vaccination efforts and ensure providers are utilizing PCV20 or PCV15+PPSV23 vaccines. All Authors: No reported disclosures
- Open Access
- 6 July 2023
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (7) , 731
Epidemiology of Coccidioidomycosis in the Veterans Health Administration, 2013–2022
We describe the epidemiology of coccidioidomycosis among a national cohort of Veterans. Using electronic health record data from adults tested for coccidioidomycosis between 1 January 2013 and 31 December 2022, we analyzed differences in baseline demographics (age, sex, race/ethnicity, birth country, comorbidities, residence, and Charlson Comorbidity Index score) between 4204 coccidioidomycosis-test-positive and 63,322 test-negative Veterans. Log-binomial regression models with adjusted risk ratios (aRRs) were used to evaluate risk factors associated with coccidioidomycosis including dissemination, hospitalization, and mortality. Case counts and incidence rates were highest in select counties in Arizona and California where Coccidioides is endemic. Coccidioidomycosis-positive Veterans were younger, more likely to be male, and Philippine-born. The risk factors most highly associated with being coccidioidomycosis-positive included Native Hawaiian/Pacific Islander (aRR 1.068 [95%CI: 1.039–1.098]), Asian (aRR 1.060 [95%CI: 1.037–1.083]), Black (aRR 1.029 [95%CI: 1.022–1.036]), American Indian/Alaska Native (aRR 1.026 [95%CI: 1.004–1.048]) race, and Hispanic/Latino ethnicity (aRR 1.021 [95%CI: 1.013–1.028]). Black race (aRR: 1.058 [95%CI: 1.037–1.081]) and Hispanic/Latino ethnicity (aRR 1.018 [95%CI: 1.0003–1.036]) were also associated with disseminated coccidioidomycosis, strengthening the evidence for the association of coccidioidomycosis, including severe infections, with specific racial and ethnic groups. There were no statistically significant differences in hospitalization within 45 days of testing or 30-day all-cause mortality. Improving our understanding of coccidioidomycosis risk factors is important for targeted prevention strategies and to reduce delays in diagnosis and ineffective treatment.
- 6 July 2023
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (7) , 731
Open AccessEpidemiology of Coccidioidomycosis in the Veterans Health Administration, 2013–2022
We describe the epidemiology of coccidioidomycosis among a national cohort of Veterans. Using electronic health record data from adults tested for coccidioidomycosis between 1 January 2013 and 31 December 2022, we analyzed differences in baseline demographics (age, sex, race/ethnicity, birth country, comorbidities, residence, and Charlson Comorbidity Index score) between 4204 coccidioidomycosis-test-positive and 63,322 test-negative Veterans. Log-binomial regression models with adjusted risk ratios (aRRs) were used to evaluate risk factors associated with coccidioidomycosis including dissemination, hospitalization, and mortality. Case counts and incidence rates were highest in select counties in Arizona and California where Coccidioides is endemic. Coccidioidomycosis-positive Veterans were younger, more likely to be male, and Philippine-born. The risk factors most highly associated with being coccidioidomycosis-positive included Native Hawaiian/Pacific Islander (aRR 1.068 [95%CI: 1.039–1.098]), Asian (aRR 1.060 [95%CI: 1.037–1.083]), Black (aRR 1.029 [95%CI: 1.022–1.036]), American Indian/Alaska Native (aRR 1.026 [95%CI: 1.004–1.048]) race, and Hispanic/Latino ethnicity (aRR 1.021 [95%CI: 1.013–1.028]). Black race (aRR: 1.058 [95%CI: 1.037–1.081]) and Hispanic/Latino ethnicity (aRR 1.018 [95%CI: 1.0003–1.036]) were also associated with disseminated coccidioidomycosis, strengthening the evidence for the association of coccidioidomycosis, including severe infections, with specific racial and ethnic groups. There were no statistically significant differences in hospitalization within 45 days of testing or 30-day all-cause mortality. Improving our understanding of coccidioidomycosis risk factors is important for targeted prevention strategies and to reduce delays in diagnosis and ineffective treatment.
- 11 January 2023
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 50 (5) , 258-264
Trends in Follow-up Testing Among Patients Positive for Chlamydia and Gonorrhea in the Veterans Health Administration, 2013 to 2019
Background: The Centers for Disease Control and Prevention (CDC) recommends testing patients with chlamydia (CT)/gonorrhea (GC) for other sexually transmitted infections (STIs) and repeating CT/GC testing 3 to 12 months later. We assessed repeat CT/GC testing and testing for HIV/syphilis in accordance with CDC guidelines in the US Veterans Health Administration. Methods: Molecular laboratory testing for CT/GC during January 1, 2013–December 31, 2020 was retrieved from Veterans Health Administration data sources. Patients were evaluated for syphilis, HIV, and repeat CT/GC testing within 1 year after a positive CT/GC test result. Differences of CT/GC-positive patients associated with receiving recommended testing were assessed using χ 2/Fisher exact tests. Results: A total of 41,630 of 1,005,761 CT (4.1%) and 17,649 of 1,013,198 GC (1.7%) results were positive. Median ages of positive CT/GC patients were 29 and 36 years, respectively. Repeat testing rates for CT/GC within 90 to 119 days were 3.9% and 2.9%, and rates within 90 to 365 days were 32.8% and 34.7%, with 8.6% and 15% being positive again, respectively. Guideline-compatible repeat testing in known HIV-positive patients nearly doubled (75.7% for CT and 67.8% for GC). The CDC-recommended HIV testing was performed for 72.4% and 65.5% CT and GC first positives, respectively, whereas syphilis testing was completed for 66.5% and 60.5% CT and GC, respectively. Compared with 25- to 34-year-old patients with CT or GC, those younger than 25 years had higher odds of guideline-discordant repeat testing but had lower odds of not receiving HIV/syphilis testing. Conclusions: Nearly two-thirds of patients did not receive recommended repeat testing, and nearly one-third were not tested for HIV/syphilis. Veterans Health Administration providers may benefit from additional education on CDC-recommended sexually transmitted infection guidelines and testing recommendations.
- 11 January 2023
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 50 (5) , 258-264
Trends in Follow-up Testing Among Patients Positive for Chlamydia and Gonorrhea in the Veterans Health Administration, 2013 to 2019
Background: The Centers for Disease Control and Prevention (CDC) recommends testing patients with chlamydia (CT)/gonorrhea (GC) for other sexually transmitted infections (STIs) and repeating CT/GC testing 3 to 12 months later. We assessed repeat CT/GC testing and testing for HIV/syphilis in accordance with CDC guidelines in the US Veterans Health Administration. Methods: Molecular laboratory testing for CT/GC during January 1, 2013–December 31, 2020 was retrieved from Veterans Health Administration data sources. Patients were evaluated for syphilis, HIV, and repeat CT/GC testing within 1 year after a positive CT/GC test result. Differences of CT/GC-positive patients associated with receiving recommended testing were assessed using χ 2/Fisher exact tests. Results: A total of 41,630 of 1,005,761 CT (4.1%) and 17,649 of 1,013,198 GC (1.7%) results were positive. Median ages of positive CT/GC patients were 29 and 36 years, respectively. Repeat testing rates for CT/GC within 90 to 119 days were 3.9% and 2.9%, and rates within 90 to 365 days were 32.8% and 34.7%, with 8.6% and 15% being positive again, respectively. Guideline-compatible repeat testing in known HIV-positive patients nearly doubled (75.7% for CT and 67.8% for GC). The CDC-recommended HIV testing was performed for 72.4% and 65.5% CT and GC first positives, respectively, whereas syphilis testing was completed for 66.5% and 60.5% CT and GC, respectively. Compared with 25- to 34-year-old patients with CT or GC, those younger than 25 years had higher odds of guideline-discordant repeat testing but had lower odds of not receiving HIV/syphilis testing. Conclusions: Nearly two-thirds of patients did not receive recommended repeat testing, and nearly one-third were not tested for HIV/syphilis. Veterans Health Administration providers may benefit from additional education on CDC-recommended sexually transmitted infection guidelines and testing recommendations.
- 1 September 2022
- Published by American Public Health Association in American Journal of Public Health
- Vol. 112 (S7) , S670-S678
Exposure Sources Among Veterans With Elevated Blood Lead Levels, United States, 2015‒2021
Objectives. To determine characteristics and sources of exposure in veterans with elevated blood lead levels (BLLs). Methods. We included users of US Veterans Health Administration care aged 18 years or older tested for BLL from October 2015 to September 2021. Prevalence of BLL 10 micrograms per deciliter (µg/dL) or higher and 25 µg/dL or higher was determined within demographic groups. Logistic regression analysis measured association of International Classification of Diseases, Tenth Revision, Clinical Modification‒coded conditions with elevated BLL. Electronic notes were reviewed for exposure sources. Results. Among 1007 unique veterans with BLL 10 µg/dL or higher, prevalence of BLL 10 µg/dL or higher and 25 µg/dL or higher peaked at 4.9 and 1.3 per 100 000 veterans, respectively (fiscal year 2019), and was highest in non-Hispanic White men and those aged 25 to 34 years. Conditions predicted by elevated BLL were attention-deficit/hyperactivity disorder (ADHD) and nausea or vomiting. Firearms represented 70.1% of occupational and 85.9% of nonoccupational exposures. Toxicology consults occurred in 17 of 298 (6%) with BLL 25 µg/dL or higher. Conclusions. Firearms were the largest exposure source among veterans with elevated BLL. Clinicians should be alert for potential conditions (including ADHD and nausea or vomiting in our study) associated with lead exposure. Standardization of care regarding toxicology referral practices is warranted. (Am J Public Health. 2022;112(S7):S670–S678. https://doi.org/10.2105/AJPH.2022.306936 )
- 1 September 2022
- Published by American Public Health Association in American Journal of Public Health
- Vol. 112 (S7) , S670-S678
Exposure Sources Among Veterans With Elevated Blood Lead Levels, United States, 2015‒2021
Objectives. To determine characteristics and sources of exposure in veterans with elevated blood lead levels (BLLs). Methods. We included users of US Veterans Health Administration care aged 18 years or older tested for BLL from October 2015 to September 2021. Prevalence of BLL 10 micrograms per deciliter (µg/dL) or higher and 25 µg/dL or higher was determined within demographic groups. Logistic regression analysis measured association of International Classification of Diseases, Tenth Revision, Clinical Modification‒coded conditions with elevated BLL. Electronic notes were reviewed for exposure sources. Results. Among 1007 unique veterans with BLL 10 µg/dL or higher, prevalence of BLL 10 µg/dL or higher and 25 µg/dL or higher peaked at 4.9 and 1.3 per 100 000 veterans, respectively (fiscal year 2019), and was highest in non-Hispanic White men and those aged 25 to 34 years. Conditions predicted by elevated BLL were attention-deficit/hyperactivity disorder (ADHD) and nausea or vomiting. Firearms represented 70.1% of occupational and 85.9% of nonoccupational exposures. Toxicology consults occurred in 17 of 298 (6%) with BLL 25 µg/dL or higher. Conclusions. Firearms were the largest exposure source among veterans with elevated BLL. Clinicians should be alert for potential conditions (including ADHD and nausea or vomiting in our study) associated with lead exposure. Standardization of care regarding toxicology referral practices is warranted. (Am J Public Health. 2022;112(S7):S670–S678. https://doi.org/10.2105/AJPH.2022.306936 )